1-10 of 10
Simon Langdon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4278: Spheroid growth in 3D alginate matrices

John Michael Dornish, Therese Andersen, Helene Heier-Baardson, Christine Markussen, Carol Ward, Peter Mullen, Simon Langdon, Ian Kunkler, David Harrison
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4278.
https://doi.org/10.1158/1538-7445.AM2011-4278
Published: 15 April 2011
View articletitled, Abstract 4278: Spheroid growth in 3D alginate matrices
Journal Articles

Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab

Dana Faratian, Alexey Goltsov, Galina Lebedeva, Anatoly Sorokin, Stuart Moodie, Peter Mullen, Charlene Kay, In Hwa Um, Simon Langdon, Igor Goryanin, David J. Harrison
Journal: Cancer Research
Cancer Res (2009) 69 (16): 6713–6720.
https://doi.org/10.1158/0008-5472.CAN-09-0777
Published: 12 August 2009
View articletitled, Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab
Open the PDF for Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab in another window
Includes: Supplementary data
Journal Articles

Gonadotropin-Releasing Hormone Receptor Levels and Cell Context Affect Tumor Cell Responses to Agonist In vitro and In vivo

Kevin Morgan, Alan J. Stewart, Nicola Miller, Peter Mullen, Morwenna Muir, Michael Dodds, Federico Medda, David Harrison, Simon Langdon, Robert P. Millar
Journal: Cancer Research
Cancer Res (2008) 68 (15): 6331–6340.
https://doi.org/10.1158/0008-5472.CAN-08-0197
Published: 01 August 2008
View articletitled, Gonadotropin-Releasing Hormone Receptor Levels and Cell Context Affect Tumor Cell Responses to Agonist In vitro and In vivo
Open the PDF for Gonadotropin-Releasing Hormone Receptor Levels and Cell Context Affect Tumor Cell Responses to Agonist In vitro and In vivo in another window
Journal Articles

Progressive loss of p160 cofactor regulation of HER2 in endocrine-resistant breast cancer

Vera Cerqueira, Catherine Naughton, David Harrison, David Cameron, Simon Langdon
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 5445.
Published: 01 May 2008
View articletitled, Progressive loss of p160 cofactor regulation of HER2 in endocrine-resistant breast cancer
Journal Articles

Estrogen receptor α (ERα ) cofactor requirement is progressively lost in endocrine resistance.

Catherine Naughton, Kenneth MacLeod, Robert Clarke, David Cameron, Simon Langdon
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 993.
Published: 01 May 2007
View articletitled, Estrogen receptor α (ERα ) cofactor requirement is progressively lost in endocrine resistance.
Journal Articles

Modified estrogen-receptor transcription complex assembly in resistant human breast cancer cell lines

Catherine Naughton, Barbara Kuske, Kenneth Macleod, William Miller, John Smyth, Robert Clarke, David Cameron, Simon Langdon
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 297–298.
Published: 01 May 2005
View articletitled, Modified estrogen-receptor transcription complex assembly in resistant human breast cancer cell lines
Journal Articles

Collateral resistance to both estrogen and erbB receptor activated growth in endocrine resistant MCF-7 breast cancer cell lines

Kate Moore, Barbara Kuske, Kenneth Macleod, Robert Clarke, John Smyth, Simon Langdon, David Cameron
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 296.
Published: 01 May 2005
View articletitled, Collateral resistance to both estrogen and erbB receptor activated growth in endocrine resistant MCF-7 breast cancer cell lines
Journal Articles

Phase II Preclinical Drug Screening in Human Tumor Xenografts: A First European Multicenter Collaborative Study

Epie Boven, Benjamin Winograd, Dietmar P. Berger, M. Patrick Dumont, Boudewijn J. M. Braakhuis, Øystein Fodstad, Simon Langdon, Heiner H. Fiebig
Journal: Cancer Research
Cancer Res (1992) 52 (21): 5940–5947.
Published: 01 November 1992
View articletitled, Phase II Preclinical Drug Screening in Human Tumor Xenografts: A First European Multicenter Collaborative Study
Open the PDF for Phase II Preclinical Drug Screening in Human Tumor Xenografts: A First European Multicenter Collaborative Study in another window
Journal Articles

Broad Spectrum Neuropeptide Antagonists Inhibit the Growth of Small Cell Lung Cancer in Vivo

Simon Langdon, Tariq Sethi, Alison Ritchie, Morwenna Muir, John Smyth, Enrique Rozengurt
Journal: Cancer Research
Cancer Res (1992) 52 (16): 4554–4557.
Published: 01 August 1992
View articletitled, Broad Spectrum Neuropeptide Antagonists Inhibit the Growth of Small Cell Lung Cancer in Vivo
Open the PDF for Broad Spectrum Neuropeptide Antagonists Inhibit the Growth of Small Cell Lung Cancer in Vivo in another window
Journal Articles

Growth of Small Cell Lung Cancer Cells: Stimulation by Multiple Neuropeptides and Inhibition by Broad Spectrum Antagonists in Vitro and in Vivo

Tariq Sethi, Simon Langdon, John Smyth, Enrique Rozengurt
Journal: Cancer Research
Cancer Res (1992) 52 (9_Supplement): 2737s–2742s.
Published: 01 May 1992
View articletitled, Growth of Small Cell Lung Cancer Cells: Stimulation by Multiple Neuropeptides and Inhibition by Broad Spectrum Antagonists in Vitro and in Vivo
Open the PDF for Growth of Small Cell Lung Cancer Cells: Stimulation by Multiple Neuropeptides and Inhibition by Broad Spectrum Antagonists in Vitro and in Vivo in another window